Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 1/20 | 0.61 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.61 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.61 |
| ▸ | MMP2 | P08253 | 6/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | KAT6A | Q92794 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | MMP9 | P14780 | 4/20 | 0.51 |
| ▸ | ADAMTS4 | O75173 | 3/20 | 0.51 |
| ▸ | F2 | P00734 | 1/20 | 0.51 |
| ▸ | MMP13 | P45452 | 3/20 | 0.50 |
| ▸ | MMP8 | P22894 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.49 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.49 |
| ▸ | PKLR | P30613 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7340546 | 1.00 | SLC1A3 (0.61) | SLC1A3SLC1A2SLC1A1MMP2ALDH1A1 | |
| SCHEMBL6964707 | 0.87 | SLC1A3 (0.64) | SLC1A3SLC1A2SLC1A1MMP2ALDH1A1 | |
| SCHEMBL15731854 | 0.87 | SLC1A3 (0.60) | SLC1A3SLC1A2SLC1A1MMP2ALDH1A1 | |
| SCHEMBL8388664 | 0.87 | SLC1A3 (0.60) | SLC1A3SLC1A2SLC1A1MMP2ALDH1A1 | |
| SCHEMBL8388668 | 0.87 | SLC1A3 (0.60) | SLC1A3SLC1A2SLC1A1MMP2ALDH1A1 | |
| SCHEMBL15708513 | 0.87 | SLC1A3 (0.60) | SLC1A3SLC1A2SLC1A1MMP2ALDH1A1 | |
| SCHEMBL7955730 | 0.87 | SLC1A3 (0.64) | SLC1A3SLC1A2SLC1A1MMP2ALDH1A1 | |
| SCHEMBL30919401 | 0.87 | SLC1A3 (0.60) | SLC1A3SLC1A2SLC1A1MMP2ALDH1A1 | |
| SCHEMBL3310154 | 0.86 | MMP2 (0.71) | SLC1A3SLC1A2SLC1A1MMP2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL7654060 | 0.86 | SLC1A3 (0.62) | SLC1A3SLC1A2SLC1A1MMP2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1505062-A1 | Heterocyclic derivatives and their use as antithrombotic agents | Akzo Nobel N.V. (NL) | 2005-02-09 | — | — | EP | disclosed |
| US-6797710-B2 | CARDIOVASCULAR DISORDERS; SERINE PROTEASE INHIBITOR; ADMINISTERING BY MOUTH; BIOAVAILABILITY | AKZO NOBEL N.V. (NL) | 2004-09-28 | — | — | US | disclosed |
| US-20030130270-A1 | Heterocyclic derivatives and their use as antithrombotic agents | MERCK SHARP & DOHME B.V. (NL) | 2003-07-10 | — | — | US | disclosed |
| US-6444672-B1 | ORAL BIOVAILABILITY; INHIBITORS OF THROMBIN AND/OR FACTOR XA; SERINE PROTEASE INHIBITOR | AKZO NOBEL N.V. (NL) | 2002-09-03 | — | — | US | disclosed |
| US-6432955-B1 | ANTICOAGULANTS | AKZO NOBEL N.V. (NL) | 2002-08-13 | — | — | US | disclosed |
| US-6194409-B1 | SERINE PROTEASE INHIBITOR; BIOAVAILABILITY WHEN ADMINISTERED BY MOUTH | AKZO NOBEL N.V. (NL) | 2001-02-27 | — | — | US | disclosed |
| EP-0975600-A1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS ANTITHROMBOTIC AGENTS | Akzo Nobel N.V. (NL) | 2000-02-02 | — | — | EP | disclosed |
| US-5847125-A | Amino acid derivatives with anticholecystokinin activity | JAMES BLACK FOUNDATION LIMITED (GB) | 1998-12-08 | — | — | US | disclosed |
| WO-1998047876-A1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS ANTITHROMBOTIC AGENTS | AKZO NOBEL N.V. (NL) | 1998-10-29 | — | — | WO | disclosed |
| US-5741792-A | ANTICOAGULANTS OF SULFONAMIDO HETEROCYCLIC THROMBIN INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-04-21 | — | — | US | disclosed |
| US-5741799-A | ANTICOAGULANTS OF SULFONAMIDO HETEROCYCLIC THROMBIN INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-04-21 | — | — | US | disclosed |
| EP-0625141-B1 | AMINO ACID DERIVATIVES WITH ANTICHOLECYSTOKININ ACTIVITY | BLACK JAMES FOUNDATION (GB) | 1997-04-16 | — | — | EP | disclosed |
| US-5583146-A | Heterocyclic thrombin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-12-10 | — | — | US | disclosed |
| EP-0625141-A1 | AMINO ACID DERIVATIVES WITH ANTICHOLECYSTOKININ ACTIVITY. | BLACK JAMES FOUNDATION (GB) | 1994-11-23 | — | — | EP | disclosed |
| EP-0623595-A1 | Guanidinyl- or amidinyl-substituted heterocyclic thrombin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 1994-11-09 | — | — | EP | disclosed |
| WO-1993014066-A1 | AMINO ACID DERIVATIVES WITH ANTICHOLECYSTOKININ ACTIVITY | JAMES BLACK FOUNDATION LIMITED (GB) | 1993-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130270-A1 | Heterocyclic derivatives and their use as antithrombotic agents | F2, F12, VKORC1 | SLC1A3 4435/4885SLC1A2 4287/4885SLC1A1 3647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.